



## **MPX Provides Additional and Updated Disclosures in Revised Management's Discussion and Analysis**

TORONTO, July 25, 2018 -- **MPX Bioceutical Corporation** ("MPX" or the "Company") (CSE:MPX) (OTC:MPXEF) announced that it has filed today a Revised and Restated Management's Discussion and Analysis (the "**Revised MD&A**") as at, and for, the three and nine month periods ended December 31, 2017.

The Revised MD&A supersedes the previous MD&A for the same period (the "**Original MD&A**").

The Ontario Securities Commission (the "**OSC**"), in connection with a staff review of the Company's filings requested the below revisions to the Original MD&A.

The Revised MD&A provides additional disclosures related to the Company's operations in the United States cannabis industry and corrects typographic and grammatical issues. These additional disclosures were included to conform to the guidance provided in CSA Staff Notice 51-352 (Revised) – *Issuers with U.S. Marijuana-Related Activities* (the "**Staff Notice**").

The Revised MD&A includes enhanced disclosure regarding each of the Company's material assets and investments in the United States, including describing whether each asset or investment constitutes "direct", "indirect" or "ancillary" involvement in the United States marijuana industry (as such concepts are defined in the Staff Notice). The Revised MD&A also includes disclosures regarding the regulatory framework in each United States jurisdiction in which the Company operates, as well as disclosures regarding its compliance with applicable laws and regulatory requirements in such jurisdictions. The Revised MD&A includes a description of the Company's systems for monitoring compliance with applicable laws and the regulatory requirements in each applicable United States jurisdiction. The Company, in this disclosure, has expanded the risk factor disclosure relating to the Company's involvement in the United States cannabis industry.

The Revised MD&A also includes updates and clarifications regarding the Company's Financial Statements for the nine months ended December 31, 2017.

Other than as expressly set forth above, the Revised MD&A does not reflect any events that occurred after the date of the filing of the Original MD&A.

The Revised MD&A was filed simultaneously with this press release on SEDAR at [www.sedar.com](http://www.sedar.com).

### **About MPX Bioceutical Corporation**

MPX, through its wholly-owned subsidiaries in the U.S., provides substantial management, staffing, procurement, advisory, financial, real estate rental, logistics and administrative services to three medicinal cannabis enterprises in Arizona operating under the Health for Life (dispensaries) and the award-winning Melting Point Extracts (high-margin concentrates wholesale) brands. The successful Health for Life brand operates in the rapidly growing Phoenix Metropolitan Statistical Area. With the acquisition of The Holistic Center, MPX added another operating medical cannabis enterprise to its footprint in Arizona.

Green Mart of Nevada NLV, LLC ("**GreenMart NV**") is an award winning licensed cultivation, production and wholesale business, licensed for both the medical and "adult-use" sectors in Las Vegas, Nevada, and is already selling wholesale into the Nevada medical cannabis market. GreenMart NV has also optioned suitable locations and intends to enter the higher-margin retail arena by applying for at least two dispensary licenses in the Las Vegas market which will operate under the "Health for Life" brand.

In Massachusetts, MPX is building out and will operate a cultivation and production facility as well as up to three dispensaries and manages three full service dispensaries and one producer in Maryland.

In Canada, MPX has acquired Canveda, which has received its cultivation license from Health Canada, will operate a cultivation and production facility in Peterborough, Ontario. The Company also leases a property in Owen Sound, Ontario, for which an application to Health Canada has been made for a cannabis production and sales license. In addition, the Company will continue its efforts to develop its legacy nutraceuticals business.

### **Cautionary Statement Regarding Forward-Looking Information**

*This news release and the documents referred to herein, include certain "forward-looking statements" under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release and the documents referred to herein include, but are not limited to, MPX's objectives and intentions. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties and other factors, which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic and*

*social uncertainties; litigation, legislative, environmental and other judicial, regulatory, political and competitive developments; delay or failure to receive board, shareholder or regulatory approvals; those additional risks set out in MPX's public documents filed on SEDAR at [www.sedar.com](http://www.sedar.com); and other matters discussed in this news release. Although MPX believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, MPX disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.*

**On behalf of the Board of Directors**

*MPX Bioceutical Corporation (formerly The Canadian Bioceutical Corporation)  
W. Scott Boyes, Chairman, President and CEO*

For further information, please contact:

MPX Bioceutical Corporation (formerly The Canadian Bioceutical Corporation)  
W. Scott Boyes, Chairman, President and CEO  
T:+1-416-840-3725  
info@mpxbioceutical.com  
www.mpxbioceutical.com

**Media Contact:**

Anne Donohoe  
KCSA Strategic Communications  
212-896-1265  
adonohoe@kcsa.com

**Investor Contact:**

Phil Carlson / Elizabeth Barker  
KCSA Strategic Communications  
212-896-1233 / 212-896-1203  
pcarlson@kcsa.com / ebarker@kcsa.com